research A comparative study on therapeutic efficacy between topical dinitrochlorobenzene and topical betamethasone in alopecia areata
DNCB is more effective than betamethasone for hair regrowth but has more side effects.
Search
for
Sort by
Research
480-510 / 1000+ results research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
Deucravacitinib helped a man regrow hair significantly.
research SnapshotDx Quiz: May 2020
BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
research Pulse cyclophospamide in severe lupus nephritis: Southern Indian experience.
IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients.
research 28665 Cutaneous T-cell lymphoma (CTCL) outcomes during COVID-19
CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
research Alopecia areata and relapsing polychondritis or mosaic autoimmunity? The first experience of co-trimoxazole treatment
Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.
research Hair Dye as a Potential Trigger for Relapse of Anti-GBM Disease: A Case Report
Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.
research Arthritis drug spurs hair regrowth in alopecia patient
An arthritis drug helped a person with severe hair loss regrow their hair.
research Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
Baricitinib is a promising treatment for alopecia areata.
research Intradermal Injection of Bleomycin Shows Preliminary Evidence of Dermal Fibrosis in a Mouse Model
Bleomycin injections in mice cause skin thickening and hair loss.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Alopecia universalis during treatment with leflunomide and adalimumab - Case report
A patient lost all their hair while on rheumatoid arthritis medication.
research Concomitant Alopecia Areata and Profound Bone Marrow Suppression: An Unusual Manifestation of Azathioprine Toxicity
Azathioprine can cause unexpected hair loss and severe bone marrow issues, so careful monitoring is needed.
research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: A retrospective study
Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.
research Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis
A woman developed severe kidney injury from using simvastatin with ciclosporin, highlighting the need for careful monitoring when combining these drugs.
research Efficacy and safety of baricitinib in patients with refractory alopecia areata
Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
research Best dilution of the best corticosteroid for intralesional injection in the treatment of localized alopecia areata in adults
BD 1/4 dilution is the best for treating localized alopecia areata in adults.
research Pityriasis rubra pilaris unveiling a case of a new onset hepatitis C infection
A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.
research Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta‐Analysis
Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research Cytostatics and immunosuppressive drugs
Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.